Radiolabeled RGD peptides move beyond cancer: PET imaging of delayed-type hypersensitivity reaction

Journal of Nuclear Medicine

Volumn 46, Issue 1, 2005, Pages 2-4

  Lewis, Michael R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; CANCER INHIBITION; CANCER STAGING; CHRONIC INFLAMMATION; DELAYED HYPERSENSITIVITY; GLYCOSYLATION; ISOTOPE LABELING; MELANOMA; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TARGET CELL; XENOGRAFT; ANIMAL; ARTICLE; HUMAN; IMAGE ENHANCEMENT; METHODOLOGY; NEOPLASM; SCINTISCANNING;

ANIMALS; HUMANS; HYPERSENSITIVITY, DELAYED; IMAGE ENHANCEMENT; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 15044364494     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Pierschbacher MD, Ruoslahti E. The cell attachment activity of fibronectin can be duplicated by small fragments of the molecule. Nature. 1984;309:30-33.
2. Smith JW, Cheresh DA. The arg-gly-asp binding domain of the vitronectin receptor: photoaffinity crosslinking implicates amino acid residues 61-203 of the β subunit. J Biol Chem. 1988;263:18726-18731.
3. 3 for angiogenesis. Science. 1994;264:569-571.
4. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998; 54:541-548.
5. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
6. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-1038.
7. Pasqualini R, Koivunen E, Ruoslahti E. αv Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
8. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
9. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40: 1061-1071.
10. van Hagen PM, Breeman WAP, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186-198.
11. Haubner R, Wester H-J, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
12. l8F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61:1781-1785.
13. Beer AJ, Haubner R, Essler M, et al. Non invasive imaging of αvβ3-expression with F-18-galacto-RGD and PET: initial results in patients [abstract]. J Nucl Med. 2004;45(suppl):192P.
14. 3 integrin binding peptides in a nude mouse model. Cancer Res. 2002; 62:6146-6151.
15. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641-646.
16. 18F-galacto-RGD. J Nucl Med. 2005;46:184-189.
17. Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003;170:2147-2152.
18. Creamer D, Allen M, Sousa A, Poston R, Barker J. Altered vascular endothelium integrin expression in psoriasis. Am J Pathol. 1995;147:1661-1667.
19. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis. 2002;61(suppl 2):ii96-ii99.